Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2022-11-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder of the company. It details the number of shares pledged, the proportion of shares involved, pledge start and end dates, and the pledgee. There is no financial data, no discussion of financial results, no meeting materials, no voting results, no legal proceedings, and no mention of report publication. The content is a regulatory announcement about share pledging, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short and it is an announcement rather than a report or detailed filing.
2022-11-01 Chinese
华泰联合证券有限责任公司关于海思科医药集团股份有限公司非公开发行股票会后事项承诺函
Regulatory Filings Classification · 95% confidence The document is a commitment letter from Huatai United Securities Co., Ltd. regarding post-issuance matters of a non-public stock issuance by Hisun Pharmaceutical Group Co., Ltd. It references regulatory approvals, audit reports, and compliance with securities regulations. The document is relatively short (2390 characters) and primarily serves as a formal attestation and compliance confirmation related to the non-public issuance of shares. It does not contain financial statements or detailed financial data itself, but rather assurances and confirmations about the issuance process and related matters. This fits the profile of a Regulatory Filing (RNS), as it is a compliance and regulatory communication rather than a full financial report or announcement of voting results, management changes, or capital changes.
2022-11-01 Chinese
北京市中伦律师事务所关于海思科医药集团股份有限公司非公开发行股票会后事项承诺函
Regulatory Filings Classification · 95% confidence The document is a legal commitment letter from a law firm regarding post-issuance matters of a non-public stock offering by a pharmaceutical company. It references regulatory approvals, audit reports, and compliance with securities regulations, but it does not contain financial statements or detailed financial data itself. The document is relatively short (2740 characters) and serves as a formal attestation or certification related to the issuance process rather than a full financial report or announcement of results. It fits best as a Regulatory Filing (RNS) because it is a compliance-related legal document that does not fall under other specific categories like Annual Report, Interim Report, or Capital Update.
2022-11-01 Chinese
海思科医药集团股份有限公司关于非公开发行股票会后事项承诺函
Regulatory Filings Classification · 95% confidence The document is a formal letter titled '关于非公开发行股票会后事项承诺函' which translates to 'Commitment Letter Regarding Post-Meeting Matters of Non-Public Stock Issuance'. It is addressed to the China Securities Regulatory Commission and discusses the company's compliance and status following the approval of a non-public issuance of A shares. The document references regulatory notices and audit reports but does not contain financial statements or detailed financial data itself. It is a post-approval commitment letter confirming no adverse events or changes affecting the issuance. The document length is 2240 characters, which is relatively short and consistent with a regulatory or compliance letter rather than a full report. Therefore, it is not an Annual Report, Interim Report, or Audit Report but rather a regulatory filing related to the non-public stock issuance process. This fits best under Regulatory Filings (RNS) as it is a compliance and attestation document without substantive financial data or report content.
2022-11-01 Chinese
信永中和会计师事务所（特殊普通合伙）关于海思科医药集团股份有限公司非公开发行股票会后事项承诺函
Regulatory Filings Classification · 95% confidence The document is a letter from an auditing firm (信永中和会计师事务所) regarding the post-issuance matters of a non-public stock issuance by 海思科医药集团股份有限公司. It references audit reports for fiscal years 2019, 2020, and 2021, confirms no major adverse events affecting the issuance, and complies with regulatory notices from the China Securities Regulatory Commission. The document is a formal commitment letter (承诺函) related to the non-public issuance process, not the audit report itself or the annual report. It does not contain financial statements or detailed audit results but rather assurances and confirmations about the issuance and related compliance. The document length is short (2170 characters), and it serves as a post-issuance compliance and commitment letter. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a full audit report or financial report.
2022-11-01 Chinese
华泰联合证券有限责任公司关于海思科医药集团股份有限公司非公开发行A股股票之补充尽职调查报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "Supplemental Due Diligence Report" by Huatai United Securities Co., Ltd. regarding a non-public issuance of A shares by Hisun Pharmaceutical Group Co., Ltd. It contains detailed financial data for the period January to September 2022, including revenue, profit, and net asset figures, as well as analysis of performance changes and compliance with issuance conditions. The document references regulatory approvals and compliance with securities laws, and it is prepared by the sponsor institution as part of the issuance process. The content is focused on due diligence and financial performance analysis related to a capital raising event, not a full annual or interim report, nor an earnings release or audit report. It is a detailed report supporting a capital/financing update (non-public share issuance). Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (5598 characters) and detailed financial data support this classification with high confidence.
2022-11-01 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.